We demonstrated that targeting GPC-1 with anti-GPC-1 mAb (clone 1–12) had a strong antitumour effect via ADCC and CDC in a GPC-1-positive ESCC xenograft model.19,20 We showed the efficacy of anti-GPC-1 mAb after confirming GPC-1 expression in PDAC. The gene discussed is GPC1; the disease is esophageal squamous cell carcinoma.